- Home
- PHAR vs CYH Comparison
PHAR vs CYH Comparison
Compare PHAR & CYH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- CYH
- Stock Information
- Founded
- PHAR 1988
- CYH 1985
- Country
- PHAR Netherlands
- CYH United States
- Employees
- PHAR N/A
- CYH N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- CYH Hospital/Nursing Management
- Sector
- PHAR Health Care
- CYH Health Care
- Exchange
- PHAR Nasdaq
- CYH Nasdaq
- Market Cap
- PHAR 718.1M
- CYH 482.7M
- IPO Year
- PHAR N/A
- CYH 1991
- Fundamental
- Price
- PHAR $10.27
- CYH $3.41
- Analyst Decision
- PHAR Strong Buy
- CYH Hold
- Analyst Count
- PHAR 3
- CYH 8
- Target Price
- PHAR $30.00
- CYH $4.27
- AVG Volume (30 Days)
- PHAR 4.3K
- CYH 2.5M
- Earning Date
- PHAR 07-31-2025
- CYH 07-23-2025
- Dividend Yield
- PHAR N/A
- CYH N/A
- EPS Growth
- PHAR N/A
- CYH N/A
- EPS
- PHAR N/A
- CYH N/A
- Revenue
- PHAR $320,708,000.00
- CYH $12,653,000,000.00
- Revenue This Year
- PHAR $13.31
- CYH N/A
- Revenue Next Year
- PHAR $7.68
- CYH $3.49
- P/E Ratio
- PHAR N/A
- CYH N/A
- Revenue Growth
- PHAR 24.13
- CYH 1.05
- 52 Week Low
- PHAR $6.65
- CYH $2.24
- 52 Week High
- PHAR $12.61
- CYH $6.29
- Technical
- Relative Strength Index (RSI)
- PHAR 49.06
- CYH 51.68
- Support Level
- PHAR $10.46
- CYH $3.31
- Resistance Level
- PHAR $11.49
- CYH $3.62
- Average True Range (ATR)
- PHAR 0.34
- CYH 0.16
- MACD
- PHAR -0.12
- CYH 0.01
- Stochastic Oscillator
- PHAR 31.46
- CYH 70.45
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About CYH Community Health Systems Inc.
Community Health Systems Inc is a publicly owned hospital operator in the United States. The company also owns four home health agencies and provides management and consulting services to independent hospitals. The firm derives revenue through a broad range of general and specialized hospital healthcare services and outpatient services.